Sheaff Brock Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Sheaff Brock Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,400	Closed	-$239K	–	520
2020 Q4	$239K	Buy	+1,400	New	+$207K	0.02%	384
2020 Q3	–	Sell	-3,000	Closed	-$481K	–	496
2020 Q2	$481K	Hold	3,000	–	–	0.05%	221
2020 Q1	$293K	Hold	3,000	–	–	0.04%	271
2019 Q4	$387K	Hold	3,000	–	–	0.04%	283
2019 Q3	$226K	Buy	3,000 +1,350	+82%	+$159K	0.02%	377
2019 Q2	$251K	Buy	+1,650	New	+$201K	0.03%	370

Other funds holding SRPT

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Sheaff Brock Investment Advisors's SRPT Position: Q1 2021 in Review

Sheaff Brock Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2021, closing a stake of 1,400 shares — an estimated $239K sold.

Sheaff Brock Investment Advisors first reported a position in SRPT in Q2 2019 and held it in 6 quarters. The position peaked at $481K in Q2 2020. 366 funds tracked by Wall St. Rank hold SRPT as of Q1 2021.

Sheaff Brock Investment Advisors reported no remaining Sarepta Therapeutics position as of Q1 2021 after selling out during the quarter.
Sheaff Brock Investment Advisors sold 1,400 Sarepta Therapeutics shares in Q1 2021, an estimated $239K.
Sheaff Brock Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2019 and held it in 6 quarters.
Sheaff Brock Investment Advisors's Sarepta Therapeutics position peaked at $481K in Q2 2020.
366 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2021.

Based on Sheaff Brock Investment Advisors's 13F filing for Q1 2021, filed 11 May 2021.